CardioMetaIQ is anchored to the phase-3 trials that defined GLP-1 therapy in obesity-related HFpEF. Every calibration target, generalization and validation check traces to a published source.
A guided motion demo of the clinical workspace — phenotype entry, the graded response, safety screen, 52-week trajectories and the validation tabs.
The primary calibration anchor for weight-driven hemodynamics and the headline e_W parameter. SUMMIT also supplies the per-patient cohort scatter reproduced in Figure 2.
Calibrates the symptom and functional-class trajectory under semaglutide in the non-diabetic obese HFpEF population, and rescales e_W across the GLP-1 class.
Extends calibration to the type-2-diabetes phenotype, supporting the diabetes-status generalization the twin applies when the phenotype carries T2DM.
The held-out external validation target (Figure 5): left-atrial volume, E/e′, RV areas and LV mass. The twin reproduces the LA volume endpoint on target without a dedicated state.
Every action recorded to a SHA-256 hash-chained audit ledger (§11.10(e)).
Software-as-a-Medical-Device with a predetermined change-control plan for model updates.
Phenotype ingest via FHIR R4 with LOINC and RxNorm coding; no manual re-entry.
Clinical decision support; nothing is auto-prescribed and outputs are not diagnostic.
CardioMetaIQ is available to clinical and research partners for validation studies under the SaMD framework. Tell us about your cohort and we'll set up scoped access.
deepanjan.datta@hemodynamiq.com